Abbott leads fragmented sensor-based smart catheters market

By AI, Created 4:40 PM UTC, May 18, 2026, /AGP/ – Abbott Laboratories led global sales in the sensor-based smart catheters market in 2024, while the top 10 players held just 17% of revenue. The ranking underscores a crowded field where contact force sensing, real-time monitoring and AI-enabled catheter systems are shaping competition.

Why it matters: - The sensor-based smart catheters market is growing around technologies that can improve procedural accuracy, patient safety and real-time cardiac monitoring. - Fragmentation gives specialized device makers room to compete, but it also raises the bar on regulatory clearance, engineering precision and clinical reliability. - Abbott Laboratories held the largest global sales share in 2024 at 3%, showing that no single company has broad market control.

What happened: - The Business Research Company published a market analysis on the sensor-based smart catheters market and its competitive landscape. - Abbott Laboratories led global sales in 2024 with a 3% market share. - Johnson & Johnson, Boston Scientific Corporation and Cardinal Health Inc. each held 3% share. - Medtronic plc, COOK Medical LLC, Becton Dickinson and Company, TE Connectivity Corporation, Smiths Group and ICU Medical Inc. each held 2% share. - The top 10 companies accounted for 17% of total market revenue in 2024. - The report listed Abbott Laboratories, Johnson & Johnson, Boston Scientific Corporation, Cardinal Health Inc., Medtronic plc, COOK Medical LLC, Becton Dickinson and Company, TE Connectivity Corporation, Smiths Group and ICU Medical Inc. as leading companies. - The report also named major players including Biotronik SE & Co. KG, Medline Industries LP, Freudenberg Medical LLC, Spacelabs Healthcare Inc., Bactiguard AB, MicroPort Scientific Corporation, Acutus Medical Inc., Stereotaxis Inc., Osypka AG, Baylis Medical Company Inc. and CathRx Ltd.

The details: - Abbott Laboratories’ cardiovascular and structural heart division offers sensor-enabled catheter systems, pressure and flow monitoring devices, interventional cardiology solutions and minimally invasive diagnostic and therapeutic tools. - Major raw material suppliers include Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Johnson & Johnson, Edwards Lifesciences Corporation, Koninklijke Philips N.V., Siemens Healthineers AG, GE HealthCare Technologies Inc., Terumo Corporation, Cardinal Health Inc., ICU Medical Inc., Lepu Medical Technology Co. Ltd., Biotronik SE & Co. KG, AngioDynamics Inc., Integer Holdings Corporation, Nipro Corporation, Heraeus Medical Components and Freudenberg Medical LLC. - Major wholesalers and distributors include McKesson Corporation, AmerisourceBergen Corporation, Owens & Minor Inc., Medline Industries LP, Henry Schein Inc., Patterson Companies Inc., Concordance Healthcare Solutions Inc., Morris & Dickson Co. LLC, H. D. Smith Wholesale Drug Co., CuraScript SD, Movianto GmbH, Uniphar Group plc and Phoenix Medical Supplies Ltd. - Major end users include Cleveland Clinic, Mount Sinai Health System, Kaiser Permanente, NewYork-Presbyterian Hospital, Cedars-Sinai Medical Center, Apollo Hospitals Enterprise Limited, Fortis Healthcare Limited, Manipal Hospitals, Narayana Health, Singapore General Hospital, National University Hospital Singapore, Royal Melbourne Hospital, Seoul National University Hospital, Tokyo University Hospital and Cleveland Clinic Abu Dhabi. - Contact force sensing technology is becoming a central product trend because it measures catheter-tissue interaction in real time. - The technology is designed to improve procedural accuracy, safety and clinical outcomes in cardiac interventions. - In May 2025, Abbott Laboratories launched the TactiFlex sensor-enabled ablation catheter for atrial fibrillation treatment. - The TactiFlex catheter uses a flexible laser-cut tip, contact force sensing and integration with the EnSite X EP System to support cardiac mapping, lesion formation and procedural safety.

Between the lines: - The market’s modest concentration suggests competition is driven more by product performance and regulatory execution than by scale alone. - The supplier, distributor and end-user lists point to a broad commercial ecosystem that supports both hospital adoption and technology rollout. - AI-driven imaging and analytics, along with modern interventional cardiology infrastructure, are emerging as positioning themes for companies chasing share.

What’s next: - Companies are expected to lean harder into strategic collaborations, product innovation and regional expansion. - Continued demand for precision-guided catheterization and continuous physiological monitoring should keep contact force sensing and integrated digital systems in focus. - Abbott’s May 2025 launch suggests competition will likely center on feature-rich, sensor-enabled catheter platforms tied to broader electrophysiology systems.

The bottom line: - Sensor-based smart catheters remain a competitive, fragmented market where innovation in sensing, monitoring and data integration is the main path to growth.